Management
Dr. Ram Burgi-Krishnamurthy
CEO, Director
Dr. Bürgi-Krishnamurthy is a seasoned healthcare industry executive with over 24 years of experience in global strategic operations for both public and private corporations in the healthcare sector. He is currently the Managing Director of Health Bytes, LLC, a financial and management consultancy firm focused on the pharmaceutical, biotechnology, medical technology, digital health, and life sciences industries.
Dr. Bürgi-Krishnamurthy is a seasoned healthcare industry executive with over 24 years of experience in global strategic operations for both public and private corporations in the healthcare sector. He is currently the Managing Director of Health Bytes, LLC, a financial and management consultancy firm focused on the pharmaceutical, biotechnology, medical technology, digital health, and life sciences industries.
Additionally, Dr. Bürgi-Krishnamurthy serves as a senior consultant for Celtic Asset and Equity Partners in Dublin, specializing in SPACs. He is also the Chief Financial Officer of AXIOS Sustainable Growth Acquisition Corporation (NYSE: AXAC) which aims to acquire Agtech and plant-based protein technology companies. Between 2019 and 2022, he was a member of the Board of Directors of Thermal Medical Switzerland Ltd., a Swiss-based company specializing in the development and global marketing of medical devices.
Before his current engagements, Dr. Bürgi-Krishnamurthy held senior sales and marketing positions at Radiometer Medical ApS, a subsidiary of Danaher Corporation (NYSE: DHR), and has held senior positions in healthcare business management for companies such as Catalent, Inc. (NYSE: CTLT), Octapharma AG, Thermo Fisher Scientific, Inc. (NYSE: TMO), Straumann Holding AG (XSWX: STMN), and Deloitte Consulting AG.
Dr. Bürgi-Krishnamurthy holds a PhD from the University of Zurich, Switzerland and an MBA from the Strathclyde Business School in the UK.
Alexander V. Schinzing
Chairman, Director
Alexander V. Schinzing is the managing director of Celtic Asset & Equity Partners. He has been corporate secretary of numerous SPACs and a serial SPAC initiator. Currently he serves as CEO of Financial Strategies Acquisition Corp., a Nasdaq listed SPAC [FXCO].
Alexander V. Schinzing is the managing director of Celtic Asset & Equity Partners. He has been corporate secretary of numerous SPACs and a serial SPAC initiator. Currently he serves as CEO of Financial Strategies Acquisition Corp., a Nasdaq listed SPAC [FXCO] and has been involved in several SPAC initiations. Alexander is a member of the Institute of Directors in Ireland since August 2019. Before this, he worked as a managing consultant at The Tax Saving Corporation where he focused on the development of companies, business structure analysis, and company incorporation. From 2016 to 2018, he served as Vice-Chairman of the R.O.M AG supervisory board. Earlier in his career, Alexander worked for KPMG Consulting AG and Westlaw, a subsidiary of Thomson Reuters.
Alexander Schinzing holds a law degree from Georg-August-University and was admitted as an attorney in 2005.
Dr. Madeleine Billeter
Board Member
Dr. Madeleine Billeter is a highly experienced medical professional with a strong background in both medicine and the pharmaceutical industry. Madeleine holds two Board Certifications from the Swiss Medical Association in Internal Medicine and Pharmaceutical Medicine.
Dr. Madeleine Billeter is a highly experienced medical professional with a strong background in both medicine and the pharmaceutical industry. Madeleine holds two Board Certifications from the Swiss Medical Association in Internal Medicine and Pharmaceutical Medicine.
With over 25 years of experience in the pharmaceutical industry, Madeleine started her career as a Clinical Research Physician at Merck Sharp & Dohme. She held various national and international positions in Medical Affairs at AstraZeneca. She later became a Global Medical Affairs Director at BiogenIdec International, where she developed a passion for Multiple Sclerosis (MS) treatment. This area of expertise she continued to work on during her time at Genzyme (later Sanofi).
In 2017, Madeleine joined Sarepta as the Executive Director Medical Affair EMEA, where she focused on the treatment of Duchenne Muscular Dystrophy and Limb Girdle Muscular Dystrophy, with a particular emphasis on the gene therapy program. Currently, Madeleine works as a consultant for Roche, serving as the Global Lead Medical Affairs on the DMD Gene Therapy Program.
Madeleine hold a MD from the University of Zurich in Switzerland and gained clinical experience working in hospitals in Switzerland and the United States.
John Henry Boatright
Senior Science Officer – Development
John Boatright is a seasoned drug development expert with over 15 years of experience in both prescribed and over-the-counter pharmaceuticals, as well as in the cannabis industry. He is currently the Director of Drug Technology at Luminus Biosciences, a Texas-based research firm specializing in protein-bound, lipid-stabilized nanoparticles for chemotherapy and mTOR inhibitors. In 2019 and 2020, John filed four patent applications for solid nanoparticle formulations related to chemotherapies, multi-drug therapies, and cannabinoids.
John Boatright is a seasoned drug development expert with over 15 years of experience in both prescribed and over-the-counter pharmaceuticals, as well as in the cannabis industry. He is currently the Director of Drug Technology at Luminus Biosciences, a Texas-based research firm specializing in protein-bound, lipid-stabilized nanoparticles for chemotherapy and mTOR inhibitors. In 2019 and 2020, John filed four patent applications for solid nanoparticle formulations related to chemotherapies, multi-drug therapies, and cannabinoids.
In recent years, John has also served as a consultant for various healthcare companies, including MobileMED Health, a clinical diagnostic provider, and Rhapsody Labs, a cannabis processing and manufacturing company. John previously held technical and operational management roles in biotech firms, such as Trinity Laboratories, where he gained experience formulating topicals and oral capsules in a cGMP environment. Before that, he worked as a chemist for Azaya Therapeutics, developing liposomes for sterile injectables in the chemotherapy field.
John holds a Bachelor of Science degree from the University of Texas at San Antonio and received this degree while concurrently working for Luminus. As the Director of Drug Technology, he prioritizes the commercial viability of drug product candidates by identifying and mitigating risk factors early in the development cycle, allowing for a more efficient process.
David Woody
Senior Science Officer – Formulation
David Woody is a highly experienced pharmaceutical researcher and development professional with over 16 years of experience. He has a focus on injectable nanoparticles and drug formulation, and has also worked extensively in analytical chemistry, chemical processing, regulatory compliance, and laboratory management. He was instrumental in the development of the patented Lipid Albumin Stabilized Solid Nanoparticles (LASSN) technology and has been involved in the development of several notable projects.
David Woody is a highly experienced pharmaceutical researcher and development professional with over 16 years of experience. He has a focus on injectable nanoparticles and drug formulation, and has also worked extensively in analytical chemistry, chemical processing, regulatory compliance, and laboratory management. He was instrumental in the development of the patented Lipid Albumin Stabilized Solid Nanoparticles (LASSN) technology and has been involved in the development of several notable projects. He was the Director of Drug Development at Luminus Biosciences where he was responsible for the advancement of several projects, including the development of a 505(b)(2) LASSN-Paclitaxel product and a generic Abraxane product. He has also worked on a LASSN formulations for a major pharmaceutical company in their ophthalmic nano-emulsion formulation that was used in a Phase III clinical study.
Prior to his work at Luminus Biosciences, David was the Production Manager at Trinity Laboratories where he created and implemented a GMP manufacturing process for synthesizing capsaicin palmitate and was involved in all aspects of regulatory compliance for the API and finished product.
David Woody has a BS in Chemistry from the University of Texas San Antonio and has been published as a lead author for organic work performed in an academic lab. With his extensive experience in all aspects of the LASSN technology, he is in a unique position to bring LASSN products to a commercial and monetizable reality and expand on the IP to develop the next generation of nanoparticle drug products.
Dr. Reyes Tamez Guerra
Board Member
Dr. Reyes Tamez Guerra is a renowned immunologist and virologist who has made significant contributions to the field of cancer and infectious diseases. He is one of the founders of the Immunology and Virology Department at the Biological Sciences School of the Autonomous University of Nuevo León (UANL) and has been a professor of Immunology at the university since 1981. He has also served as Dean of the Biological Sciences School from 1989 to 1991 and as General Secretary (Vice-President) and President of UANL from 1991 to 2000.
Dr. Reyes Tamez Guerra is a renowned immunologist and virologist who has made significant contributions to the field of cancer and infectious diseases. He is one of the founders of the Immunology and Virology Department at the Biological Sciences School of the Autonomous University of Nuevo León (UANL) and has been a professor of Immunology at the university since 1981. He has also served as Dean of the Biological Sciences School from 1989 to 1991 and as General Secretary (Vice-President) and President of UANL from 1991 to 2000.
Dr. Tamez has published over 350 scientific papers in internationally recognized journals, with a high impact factor, and has received 20 patents. He is a member of the National Research System Level II and the Mexican National Academy of Sciences, and has held numerous positions of leadership and recognition in academia, government, and education. In 2009, he was elected to the Federal Congress as a member and President of the Science and Technology Committee. He has also been a Visiting Scholar at the Harvard School of Education in 2011 and a Fellow of the Harvard Advanced Leadership Initiative since 2012.
Dr. Tamez Guerra received his bachelor’s degree in Microbiology from the UANL, as well as a Master’s and PhD degree in Immunology from the Biological Sciences National School Instituto Politécnico Nacional. His research work has primarily focused on the development of immunotherapy for cancer and infectious diseases.